Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Instagram Outage Disrupts Thousands of U.S. Users 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
MENLO PARK, Calif., Sept. 28, 2017 -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today that company executives will present at upcoming conferences in October.
| Event: | Cell & Gene Meeting on the Mesa | ||
| Date: | October 5, 2017 | ||
| Time: | 2:15 – 2:30 p.m. PT | ||
| Location: | La Jolla, CA | ||
| Presentation: | Amber Salzman, Ph.D., president and chief executive officer | ||
| Event: | Chardan Gene Therapy Conference | ||
| Date: | October 10, 2017 | ||
| Time: | 2:00 – 2:25 p.m. ET | ||
| Location: | New York, NY | ||
| Presentation: | Amber Salzman, Ph.D., president and chief executive officer | ||
| Event: | Jefferies Gene Technology Summit Conference | ||
| Date: | October 12, 2017 | ||
| Location: | New York, NY | ||
| Panel: | Mehdi Gasmi, Ph.D., chief science and technology officer |
A live and replay video webcast of the Cell & Gene Meeting on the Mesa may be accessed by visiting www.meetingonthemesa.com/webcast/.
A live and replay audio webcast of the Chardan Gene Therapy Conference fireside chat will be available from Adverum’s website at http://investors.adverum.com.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that may offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Adverum Contact: Charles Butler Vice President, Investor Relations & Corporate Communications 650-272-6260 [email protected]
